Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
Jean‐Michel Molina(Inserm), Steven L. Chuck(San Francisco General Hospital), Bonaventura Clotet(IrsiCaixa), Jaime Andrade‐Villanueva(Hospital Civil de Guadalajara), Nicolas Margot(Gilead Sciences (United States)), Ya-Pei Liu(Gilead Sciences (United States)), Lijie Zhong(Gilead Sciences (United States)), Andrew Cheng(Gilead Sciences (United States)), Nathan Clumeck(Centre Hospitalier Universitaire de Saint-Pierre), Anthony LaMarca(Therafirst Medical Center)
Cited by 172
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
|New England Journal of Medicine|2006|886
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882
Infections with<i>Cryptococcus neoformans</i>in the Acquired Immunodeficiency Syndrome
|New England Journal of Medicine|1989|801